Editorial: Metabolic and biomechanical factors in bone fragility: new frontiers in understanding and managing osteoporosis
-
By
-
-
May 5, 2026
Clinical Report: Exploring Metabolic and Biomechanical Influences on Bone Fragility
Overview
This editorial discusses advancements in understanding and managing osteoporosis, emphasizing the importance of metabolic and biomechanical factors in bone fragility. It highlights the need for improved assessment methods and tailored treatment approaches to enhance bone health and fracture prevention.
Background
Osteoporosis is a significant public health concern characterized by skeletal fragility due to loss of bone mass and compromised bone quality. Understanding the multifactorial nature of osteoporosis, including primary and secondary causes, is crucial for effective management. The integration of metabolic and biomechanical insights into clinical practice can lead to better prevention and treatment strategies.
Data Highlights
No specific numerical data provided in the editorial.
Key Findings
- Osteoporosis can be classified into primary and secondary types, with secondary causes affecting a significant proportion of patients.
- Metabolic disturbances and systemic illnesses can exacerbate bone loss, necessitating a comprehensive understanding of these factors.
- Current research emphasizes the limitations of traditional bone mineral density (BMD) assessments in evaluating bone fragility.
- Emerging studies are exploring novel methods for detecting bone fragility and new therapeutic options to improve bone strength.
- Machine learning models are being developed to predict osteoporosis risk in older women based on clinical data.
Clinical Implications
Healthcare professionals should consider both metabolic and biomechanical factors when assessing osteoporosis risk and developing treatment plans. Enhanced diagnostic tools and tailored therapies are essential for improving patient outcomes and preventing fractures.
Conclusion
A comprehensive approach to osteoporosis management that incorporates metabolic and biomechanical insights is vital for effective prevention and treatment. Continued research and evidence generation will further enhance clinical practices in this field.
References
- Papadopoulou–Marketou N, et al., The Journal of Clinical Endocrinology & Metabolism, 2025 -- Correction to: Efficient Short-duration, Low-impact, High-intensity Osteogenic Loading for Osteoporosis in Postmenopausal Women
- Papadopoulou–Marketou N, et al., The Journal of Clinical Endocrinology & Metabolism, 2025 -- Short-duration, Low-impact, High-intensity Osteogenic Loading for Postmenopausal Osteoporosis: A Quasi-experimental Case Series Analysis
- Archives of Toxicology, 2020 -- Evaluating In Vitro Bone Models for Assessing Bone Metabolism Alterations, Osteopathies, and Fracture Healing: Navigating the Complexities of Advanced Models
- Frontiers in Endocrinology, 2026 -- Osteoporosis therapies and coronary risk: insights from vascular calcification biology and sclerostin signaling
- United States Preventive Services Taskforce, 2025 -- Recommendation: Osteoporosis to Prevent Fractures: Screening
- ScienceDirect, 2025 -- The efficacy and safety of romosozumab sequential therapy in postmenopausal women: A systematic review and meta-analysis
- Osteoporosis International, 2023 -- Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis
- Recommendation: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce
- The efficacy and safety of romosozumab sequential therapy in postmenopausal women: A systematic review and meta-analysis - ScienceDirect
- Osteoporosis International (2023) 34:1501–1529
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
